355 results on '"Michowitz, Yoav"'
Search Results
102. “Typical” electrocardiographic left ventricular outflow tract ventricular tachycardia ablated from the right heart side
103. Epicardial ablation of ventricular tachycardia: An institutional experience of safety and efficacy
104. CARDIAC REMODELING AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION
105. Clinical Outcomes of Single- versus Dual-Chamber Implantable Cardioverter Defibrillators: Lessons from the Israeli ICD Registry.
106. Left Ventricular Outflow Tract Arrhythmias: Clinical Characteristics and Site of Origin.
107. Management of Brugada Syndrome: Thirty-Three-Year Experience Using Electrophysiologically Guided Therapy With Class 1A Antiarrhythmic Drugs.
108. Abstract 19194: Cardiac MRI and Electrophysiology Study Can Risk Stratify Patients with Ventricular Tachycardia and Structurally Normal Heart
109. Response to Letter Regarding Article, “Functional Pace-Mapping Responses for Identification of Targets for Catheter Ablation of Scar-Mediated Ventricular Tachycardia”
110. Functional Pace-Mapping Responses for Identification of Targets for Catheter Ablation of Scar-Mediated Ventricular Tachycardia
111. Wide Complex Tachycardia with a Unique Mode of Termination: What Is the Mechanism?
112. Hybrid techniques and neuraxial modulation for treatment of ventricular tachycardia
113. Hybrid Ablation Therapy: Current Status and Future Development
114. Hybrid procedures for epicardial catheter ablation of ventricular tachycardia: Value of surgical access
115. Electrophysiological Differences between the Epicardium and the Endocardium of the Left Atrium
116. Neuraxial Modulation for Refractory Ventricular Arrhythmias
117. Characterization of the Arrhythmogenic Substrate in Ischemic and Nonischemic Cardiomyopathy
118. SHOULD DEFIBRILLATION THRESHOLD BE TESTED IN PATIENTS WITH CARDIAC RESYNCHRONIZATION THERAPY-DEFIBRILLATOR IMPLANTATION?
119. Non-alcoholic Wernicke's encephalopathy — unusual clinical findings
120. The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis
121. Stent thrombosis in patients treated with thienopyridines: clinical description of 10 cases
122. Number and Adhesive Properties of Circulating Endothelial Progenitor Cells in Patients With In-Stent Restenosis
123. Early onset of hyperkalemia in patients treated with low molecular weight heparin: a prospective study
124. '10 commandments' for the 2021 ESC guidelines on cardiac pacing and cardiac resynchronization therapy.
125. Células endoteliales progenitoras circulantes y pronóstico en pacientes con insuficiencia cardíaca congestiva.
126. Early onset of hyperkalemia in patients treated with low molecular weight heparin: a prospective study.
127. 803-1 The number and adhesive properties of circulating endothelial progenitor cells in patients with in-stent restenosis
128. Biophysical Parameters During Radiofrequency Catheter Ablation of Scar-Mediated Ventricular Tachycardia: Epicardial and Endocardial Applications via Manual and Magnetic Navigation.
129. The impact of peri-procedural imaging on safety and efficacy of atrial fibrillation ablation: insights from the Israeli AF Catheter Ablation Registry (ICAR).
130. Incidence and Predictors for Recurrence of Ventricular Arrhythmia Presenting During Acute Myocarditis: A Multicenter Study.
131. Evaluation of MADIT-II Risk Stratification Score Among Nationwide Registry of Heart Failure Patients With Primary Prevention Implantable Cardiac Defibrillators or Resynchronization Therapy Devices.
132. Ethnic Disparities in Patients With Atrial Fibrillation Who Underwent Pulmonary Veins Isolation: Insights from the Israeli Atrial Fibrillation Catheter Ablation Registry.
133. Post-transcatheter aortic valve implantation isolated PR prolongation: incidence and clinical significance.
134. Remote monitoring of cardiac implantable electronic devices and disease management.
135. Electrocardiographic findings in patients with arrhythmogenic cardiomyopathy and right bundle branch block ventricular tachycardia.
136. Cryoballoon-Induced Circumferential Pulmonary Vein Fibrosis, Assessed by Late Gadolinium-Enhancement Cardiac Magnetic Resonance Imaging, and Its Correlation with Clinical Atrial Fibrillation Recurrence.
137. Characteristics of Patients with Spontaneous Versus Drug-Induced Brugada Electrocardiogram: Sub-Analysis From the SABRUS.
138. Lack of magnet use during chest compressions leads to multiple inappropriate shocks by a subcutaneous implantable cardioverter-defibrillator.
139. [2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy Developed by the Task Force on cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology (ESC) With the special contribution of the European Heart Rhythm Association (EHRA)].
140. [RECOMMENDATIONS FOR CHANGING CARDIOVASCULAR SCREENING OF ATHLETES WHO ARE REQUIRED FOR PRE-PARTICIPATION SCREENING UNDER THE SPORTS LAW - A POSITION PAPER ON BEHALF OF THE ISRAEL HEART SOCIETY].
141. Lead fixation mechanism impacts outcome of transvenous lead extraction: data from the European Lead Extraction ConTRolled Registry.
142. Corrigendum to: 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: Developed by the Task Force on cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology (ESC): With the special contribution of the European Heart Rhythm Association (EHRA).
143. Implantation of cardiac electronic devices in active COVID-19 patients: Results from an international survey.
144. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy.
145. European Society of Cardiology Quality Indicators for the care and outcomes of cardiac pacing: developed by the Working Group for Cardiac Pacing Quality Indicators in collaboration with the European Heart Rhythm Association of the European Society of Cardiology.
146. Out-of-hospital cardiac arrest due to idiopathic ventricular fibrillation in patients with normal electrocardiograms: results from a multicentre long-term registry.
147. Ethnic differences in patients with Brugada syndrome and arrhythmic events: New insights from Survey on Arrhythmic Events in Brugada Syndrome.
148. Time-to-first appropriate shock in patients implanted prophylactically with an implantable cardioverter-defibrillator: data from the Survey on Arrhythmic Events in BRUgada Syndrome (SABRUS).
149. Characterization and Management of Arrhythmic Events in Young Patients With Brugada Syndrome.
150. Pharmacological Therapy in Brugada Syndrome.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.